Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
Maplight Therapeutics, Inc. submitted a Form 144 notice related to proposed sales of Common stock, filed with a broker address listed as Jefferies, 520 Madison Ave, New York. The filing date shown is 04/15/2026. The excerpt lists prior Restricted Stock Unit grants of 14,844, 7,664, and 24,222 shares with grant dates of 07/30/2023, 11/09/2023, and 05/02/2024, respectively.
Maplight Therapeutics, Inc. submission lists proposed sales of Common Stock under Form 144. The excerpt shows Restricted Stock Unit grants of 3,200 shares (07/30/2023), 1,434 shares (11/09/2023), and 6,147 shares (05/02/2024). A securities line also shows the numbers 4,896, 132,289.92, and 42,440,000 with an apparent date of 04/15/2026.
Maplight Therapeutics, Inc. submitted a Form 144 notice related to proposed sales of Common Stock through Jefferies LLC. The filing lists trade details and several RSU grants with grant dates and share counts. Quantities shown include 49,365.54 (value or shares field) and grant-related share amounts of 1,668, 853, and 3,012.
The filing names Jefferies LLC as the broker-dealer and references 04/15/2026 and NASDAQ as the market; timing and proceeds treatment are those stated in the form.
Maplight Therapeutics filed a Form 144 notifying an intended sale of 3,472 shares of common stock through Jefferies LLC. The filing also lists a dollar figure of $93,813.44 and 42,440,000 shares outstanding as of 04/15/2026. The excerpt shows recent Restricted Stock Unit Grants of 3,348, 1,545, and 6,350 shares with grant/vesting dates noted.
MapLight Therapeutics details its clinical-stage CNS drug pipeline and discovery platform focused on debilitating brain disorders. The company’s lead candidate, ML-007C-MA, is an M1/M4 muscarinic agonist–antagonist combo in Phase 2 trials for schizophrenia (ZEPHYR) and Alzheimer’s disease psychosis (VISTA), with FDA Fast Track for hallucinations and delusions in ADP.
ML-007C-MA aims to match central efficacy with reduced peripheral side effects, supported by four Phase 1 studies in 270 participants. A second program, ML-004, repurposes zolmitriptan in an IR/ER tablet for autism spectrum disorder, now in a Phase 2 IRIS trial targeting social communication deficits and irritability.
The pipeline also includes three preclinical programs (ML-009, ML-055, ML-021) built on a circuit-based neuroscience platform using optogenetics and advanced transcriptomics. As of December 31, 2025, MapLight reports a broad patent estate covering its clinical and preclinical assets and retains global rights to all programs.
MapLight Therapeutics reported a net loss of $161.2 million for 2025, wider than $77.6 million in 2024, as it accelerated clinical development. Research and development expenses rose to $138.3 million from $68.5 million, and general and administrative expenses increased to $30.7 million from $14.4 million.
The company ended 2025 with $453.1 million in cash, cash equivalents and investments and expects this to fund operations through 2027. Total assets were $479.5 million and total liabilities were $21.1 million, resulting in stockholders’ equity of $458.4 million.
MapLight highlighted several near- and mid-term catalysts. Its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia is expected to complete enrollment in April 2026, with topline data in the third quarter of 2026. The Phase 2 IRIS trial of ML-004 in autism spectrum disorder has completed enrollment, also targeting topline data in the third quarter of 2026. ML-007C-MA received FDA Fast Track designation for Alzheimer’s disease psychosis, with Phase 2 VISTA topline results anticipated in the second half of 2027, and the earlier-stage ML-055 program is expected to reach preclinical candidate nomination in 2026.
MapLight Therapeutics director Robert C. Malenka reported open‑market sales of 14,195 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The shares were sold between $18.00 and $19.15 per share across transactions on February 20–24, 2026, leaving him with 325,059 shares held directly. An additional 31,672 shares are held indirectly through the Robert C. Malenka Living Trust, for which he serves as sole trustee with voting and dispositive power, and these retained securities remain subject to a 180‑day IPO lock‑up agreement following the final prospectus dated October 26, 2025.
Robert Malenka reported multiple sales of Common stock as shown in these Form 144 entries. The excerpt lists several dispositions by Mr. Malenka, including 21,262 shares on 01/29/2026 for $394,469.63 and 12,116 shares on 02/13/2026 for $220,685.67. The records show a sequence of open‑market sales across January and February 2026.
MPLT reported insider sales via Form 144. The filing lists multiple dispositions of Common shares by Robert Malenka between 01/28/2026 and 02/20/2026, including a 21,262-share sale for $394,469.63. The transactions are described as sales following restricted stock vesting under a registered plan on 01/23/2026.